Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
Study Details
Study Description
Brief Summary
This is an open-label phase II study, with the aim of investigating the efficacy and safety of Tislelizumab + Fruquintinib combination therapy in ARID1A-mutated pMMR/MSS metastatic colorectal cancer who have been treated with standard chemotherapy that includes fluoropyrimidine, oxaliplatin, and irinotecan. Patients with hypermutated CRC that carries POLE/POLD1 mutations cannot be included.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
In this open-label phase II study, patients with ARID1A-mutated pMMR/MSS metastatic colorectal cancer who have been treated with standard chemotherapy that includes fluoropyrimidine, oxaliplatin, and irinotecan, will be scheduled for Tislelizumab (200mg ivdrip Q3W day1) + Fruquintinib (5mg/day Q3W day1-14) until intolerable toxicity, disease progression or death. Primary endpoint of this study is ORR and secondary endpoints are OS, PFS, DCR and safety.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: patients with mCRC Tislelizumab 200mg ivdrip every 3 weeks; Fruquintinib 5mg qd day 1-14, every 3 weeks |
Drug: Tislelizumab & Fruquintinib
combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent
|
Outcome Measures
Primary Outcome Measures
- Objective Response Rate (ORR) [up to 3 years]
The proportion of patients with a confirmed complete response or partial response
Secondary Outcome Measures
- Progression-Free Survival (PFS) [up to 3 years]
PFS is defined as the time from enrollment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first.
- Overall Survival (OS) [up to 3 years]
OS is defined as the time from enrollment to death due to any cause.
- Disease control rate [up to 3 years]
The proportion of patients with a best overall response of confirmed complete or partial response, or stable disease (CR+ PR + SD).
- Incidence of Treatment-Emergent Adverse Events [until 60 days after last patient last study drug treatment]
Safety and tolerance evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 5.0.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18-80 years old (including 18 and 80);
-
Histologically confirmed colorectal adenocarcinoma and biopsy pathology confirmed MSS/pMMR;
-
Gene testing confirmed ARID1A gene mutation (nonsynonymous);
-
No signs of intestinal obstruction; Or intestinal obstruction has been relieved after proximal colostomy;
-
Has received and failed ≥ 2 line of chemotherapy or progressed on or intolerable to oxaliplatin, irinotecan and fluorouracil chemotherapy after diagnosed with mCRC;
-
ECOG PS 0-2;
-
Able to swallow tablets;
-
Life expectancy of greater than 3 months;
-
Adequate bone marrow and organ function;
-
If female and of childbearing potential, must:
-
Have a negative pregnancy test ≤14 days prior to initiating study treatment
-
Agree to avoid pregnancy during and for 3 months after study treatment
If male with a partner of childbearing potential, must:
-
Agree to use adequate, medically approved, contraceptive precautions during and for 3 months after the last dose of study treatment.
-
Able and willing to provide written informed consent for the study.
Exclusion Criteria:
-
Any active autoimmune disease or history of autoimmune disease;
-
Those who are using immunosuppressive agents, or systemic or absorbable local hormone therapy to achieve immunosuppressive purpose, and continue to use within 2 weeks before enrollment;
-
Severe allergic reaction to other monoclonal antibodies;
-
Subjects with clinical symptoms of untreated active brain metastasis or meningeal metastasis;
-
Have received other PD-1 antibody therapy or other immunotherapy targeting PD-1/PD-L1 in the past;
-
Patients with high TMB (≥ 30Muts/Mb) and germline or somatic POLE/POLD1 gene mutations in the exonuclease domain;
-
There are clinical symptoms or diseases of heart that are not well controlled, such as: (a) heart failure of NYHA level 2 or above (b) unstable angina pectoris (c) myocardial infarction occurred within 1 year (d) clinically significant supraventricular or ventricular arrhythmia needs treatment or intervention;
-
Known hereditary or acquired bleeding and thrombophilia or being treated with thrombolysis or anticoagulation;
-
Urinary protein ≥ ++, or the 24-hour urine protein quantification greater than 1.0g;
-
Clinically significant bleeding symptoms or clear bleeding tendency within 3 months before enrollment;
-
Subjects with active infection;
-
Congenital or acquired immune deficiency (such as HIV infected persons), or active hepatitis (hepatitis B: HBsAg positive and HBV DNA ≥ 10^4 copies/ml; hepatitis C: HCV antibody positive);
-
Other advanced malignant tumors within 5 years (except cured skin basal cell carcinoma, cervical carcinoma in situ, ovarian cancer, thyroid cancer and breast cancer);
-
Live vaccine may be inoculated less than 4 weeks before the study medication or during the study period;
-
Known or suspected to be allergic to the study drug or to any drug given in this trial;
-
Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions that makes the subject not eligible according to the judgment of the investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sun Yat-sen University, Cancer Center | Guangzhou | Guangdong | China | 510060 |
| 2 | Xiaoshi Zhang | Guangzhou | China |
Sponsors and Collaborators
- Sun Yat-sen University
- Hutchmed
- BeiGene
Investigators
- Principal Investigator: Peirong Ding, M.D., Sun Yat-sen University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SL-B2022-653-01